Neurodegenerative Diseases Clinical Trials

36 recruitingLast updated: June 18, 2026

There are 36 actively recruiting neurodegenerative diseases clinical trials across 26 countries. Studies span Not Applicable, Phase 3, Early Phase 1, Phase 2, Phase 4. Top locations include Exeter, Devon, United Kingdom, Tianjin, Tianjin Municipality, China, Hefei, Anhui, China. Updated daily from ClinicalTrials.gov.


Neurodegenerative Diseases Trials at a Glance

36 actively recruiting trials for neurodegenerative diseases are listed on ClinicalTrialsFinder across 6 cities in 26 countries. The largest study group is Not Applicable with 11 trials, with the heaviest enrollment activity in Exeter, Tianjin, and Hefei. Lead sponsors running neurodegenerative diseases studies include University of Exeter, Tianjin Medical University, and Casa di Cura San Raffaele Cassino.

Browse neurodegenerative diseases trials by phase

Treatments under study

About Neurodegenerative Diseases Clinical Trials

Looking for clinical trials for Neurodegenerative Diseases? There are currently 36 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neurodegenerative Diseases trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neurodegenerative Diseases clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 36 trials

Recruiting
Not Applicable

Cognitive Reserve and Response to Speech-Language Intervention in Bilingual Speakers With Primary Progressive Aphasia

DementiaAlzheimer DiseaseCommunication Disorders+11 more
Stephanie Grasso60 enrolled3 locationsNCT05741853
Recruiting
Not Applicable

Retinal Hyperspectral Imaging in Neurodegenerative Diseases

DementiaAlzheimer DiseaseParkinson Disease+5 more
Center for Eye Research Australia930 enrolled1 locationNCT07545473
Recruiting
Not Applicable

Study to Evaluate the Efficacy and Safety of ATNC-MDD V1(TMS With Cognitive Training) in Mild Alzheimer's Dementia

DementiaBrain DiseasesCentral Nervous System Diseases+5 more
Advanced Technology & Communications180 enrolled11 locationsNCT06088121
Recruiting
Phase 3

A Phase 3 Study of NTLA-2001 in ATTRv-PN

Nervous system diseasePeripheral nervous system diseaseAmyloidosis+17 more
Intellia Therapeutics60 enrolled14 locationsNCT06672237
Recruiting
Phase 3

A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)

DementiaBrain DiseasesCentral Nervous System Diseases+6 more
Eli Lilly and Company1,500 enrolled141 locationsNCT05508789
Recruiting

Hereditary Spastic Paraplegia Genomic Sequencing Initiative (HSPseq)

Movement DisordersMotor Neuron DiseaseHereditary Spastic Paraplegia+3 more
Boston Children's Hospital200 enrolled1 locationNCT05354622
Recruiting
Phase 2

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

Alzheimer DementiaLate Onset Alzheimer DiseaseNeurodegenerative Diseases
University of Arizona100 enrolled10 locationsNCT04838301
Recruiting
Not Applicable

Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity

Brain DiseasesCentral Nervous System DiseasesParkinson Disease+7 more
University Hospital, Bonn130 enrolled1 locationNCT07324330
Recruiting

Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality

Motor impairmentCognitive ImpairmentNeurological Disorders+1 more
Gametherapy200 enrolled1 locationNCT07268079
Recruiting

Passive Sensor Identification of Digital Biomarkers to Assess Effects of Orally Administered Nicotinamide Riboside

Cognitive ImpairmentDementiaCognitive Dysfunction+7 more
Mclean Hospital40 enrolled1 locationNCT05245903
Recruiting

Serotonin Release in Premotor and Motor PD

Parkinson DiseasePositron Emission TomographyNeurodegenerative Diseases+3 more
University of Exeter42 enrolled1 locationNCT05516732
Recruiting

Molecular and Functional Imaging in Monogenic PD.

Parkinson DiseaseNeurodegenerative DiseasesNervous System Disorder+2 more
University of Exeter45 enrolled1 locationNCT05518617
Recruiting

Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR

Parkinson DiseaseNeurodegenerative DiseasesREM Sleep Behavior Disorder (iRBD)
University of Exeter30 enrolled1 locationNCT05205291
Recruiting

Longitudinal Investigation of I2BS in PD

Parkinson DiseasePositron Emission TomographyNeurodegenerative Diseases+3 more
University of Exeter44 enrolled1 locationNCT05516719
Recruiting
Not Applicable

Effects of Long Term Ventilation Support on the Quality of Life of ALS Patients and Their Families

Amyotrophic Lateral SclerosisNervous System DiseasesSpinal Cord Diseases+3 more
Haukeland University Hospital200 enrolled9 locationsNCT05744310
Recruiting
Phase 4

Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases

Parkinson DiseaseNeurodegenerative DiseasesParkinson Disease Psychosis
Vanderbilt University Medical Center75 enrolled1 locationNCT05357612
Recruiting

Saliva and Extracellular Vesicles for Neurodegenerative Diseases

Alzheimer DiseaseParkinson DiseaseMild Cognitive Impairment (MCI)+3 more
Fondazione Don Carlo Gnocchi Onlus242 enrolled5 locationsNCT06869135
Recruiting

Memory Deterioration in Alzheimer Disease

Magnetic Resonance ImagingAlzheimer DiseaseMemory Impairment+1 more
Norwegian University of Science and Technology30 enrolled1 locationNCT07118137
Recruiting

Beta Amyloid PET/CT in Various Aβ-Related Disease

Beta-AmyloidNeurodegenerative DiseasesAmyloid
Tianjin Medical University500 enrolled3 locationsNCT06725706
Recruiting
Not Applicable

Neurologic Stem Cell Treatment Study

Cognitive ImpairmentDementiaTraumatic Brain Injury+23 more
MD Stem Cells500 enrolled3 locationsNCT02795052